If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  Adjunct Quetiapine Delays Time to Recurrence of Any Mood Events in Bipolar Disorder: Presented at EPA By Jenny Powers MUNICH, Germany -- March 5, 2010 -- Quetiapine is significantly more effective than placebo in the control of the recurrence of mood events over long-term treatment in patients with bipolar I disorder demonstrating mixed mood events, researchers said here on March 1 at the European Psychiatric Association (EPA) 18th European Congress of Psychiatry. Eduard Vieta, MD, Clinical Institute of Neuroscience, University of Barcelona, Barcelona, Spain, and colleagues conducted a pooled analysis of 2 identically designed, multicentre, double-blind, placebo-controlled, randomised, phase 3 studies of adjunct quetiapine in 1,326 patients with bipolar I disorder. The studies aims were to determine the efficacy of quetiapine added to lithium or divalproex in preventing mood events and mixed events in patients with bipolar I disorder with mixed symptoms who presented mood symptoms at study entry. The time to recurrence of mixed events (P < .0001) was significantly delayed with quetiapine treatment. In the ITT population, 445 patients had a most recent mixed episode at study entry; of these patients, mood events were reported by fewer patients on quetiapine plus lithium/divalproex (21.0%) than on placebo plus lithium/divalproex (53.9%). These events were reported a minimum of half as often in the quetiapine versus placebo groups and included mixed (6.4% vs 22.1%), pure manic (5.0% vs 13.3%), and pure depressed events (9.6% vs 18.6%) in quetiapine and placebo groups, respectively. The time to recurrence of mood events was significantly longer for patients on quetiapine plus lithium/divalproex than for those on placebo plus lithium/divalproex for mixed (P < .0001), pure manic (P = .0007), and pure depressed events (P = .0003). Adjunct quetiapine significantly delayed time to recurrence of any mood events compared with placebo and was generally well tolerated. This analysis supported the efficacy of quetiapine for the prevention of mood events in patients with bipolar I disorder who present with mixed symptoms, a traditionally difficult to treat population. Funding for this study was provided by AstraZeneca. [Presentation title: Long-Term Efficacy of Quetiapine in Combination With Lithium or Divalproex on Mixed Symptoms in Bipolar I Disorder. Abstract PW01-37]
|
